

Council Meeting

June 17, 2022

8:30 AM – 12:00 PM EEST (Athens time)

Break at around 10:00 / 10:30 AM

Crowne Plaza Athens, Greece

Ballroom D

1. President' s Welcome (R. Kreutz)

Apologies

- Michel Azizi (*airport strike*)
- Claudio Borghi (*possibly late arrival*)
- Philippe Van de Borne (*Covid*)

Welcome of New Members

- Zoltán Jarai (Ex-officio)
- Jan Danser (Executive Officer)

2. Approval of Minutes – Council Meeting on Jan 29, 2022

(A. Januszewicz)

The meeting minutes of the last Council Meeting have been sent to all of you for approval. There has been no objection.

3. Treasurer's Reports

- 3.a ESH Financial Report (J. Polonia)
- 3.b FESH Financial Report (M. Burnier)

3.a ESH Financial Report (J. Polonia)

European Society of Hypertension, 6300 Zug

Report of the statutory auditors
on the limited statutory examination to the General Meeting of
European Society of Hypertension

Income and Expenditures as per 31.12.2021

	31.12.2021 (CHF)		31.12.2020 (CHF)
Net assets at beginning of period	1'853'869		1'813'266
Net assets at end of period	1'996'357		1'853'869
Profit/-Loss	142'488	After taxes	40'603
Total INCOME	582'287		350'779
Total EXPENDITURE	-439'799		-310'176

European Society of Hypertension, 6300 Zug

INCOME	31.12.2021 (CHF)		31.12.2020 (CHF)	
Meeting income				
Meeting Glasgow	102'969		0	
Meeting Athens	29'771		138'917	
General Meeting income	✓ 2'230		44'739	
Total Meeting income	134'970	23,2%	183'656	52.4%
Subscriptions	✓ 255'094	43,8%	41'018	11.7%
Other income				
Royalties received	129'915		119'170	34.0%
Donations	✓ 0		6'871	2.0%
Webinars/Education	✓ 20'889		0	0.0%
Endorsement for awards	41'427		0	0.0%
Dividend/Interest Securities			63	0.0%
Extraordinary income			0	0.0%
Total Other income	192'223	33,0%	126'105	35.9%
Total INCOME	582'287	100.0%	350'779	100.0%

European Society of Hypertension, 6300 Zug

EXPENDITURE

Allowance to the FESH

	31.12.2021 (CHF)	31.12.2020 (CHF)
	0 0.0%	0 0.0%
Services sold	↓ -85'924.35	-148'811.20
<i>Various meeting costs</i>	-195.55	-45'961.35
<i>Expenses Meeting Athens</i>	↓ -43'508.00	-102'849.85
<i>Awards granted</i>	-42'220.80	-
Other operating expenses	↑ -271'205.15	-131'878.71
<i>Administrative costs</i>	↑ -72'488.20	-25'990.85
<i>Legal- and professional fees</i>	-36'260.01	-49'715.91
<i>Subscriptions Journal of Hypertension</i>	↑ -110'753.60	-21'968.45
<i>expenses Webinars</i>	-17'409.76	-
<i>other expenses</i>	-2'044.25	-6'749.85
<i>Bank charges</i>	↑ -16'912.33	-7'948.70
<i>Website expenses</i>	-15'337.00	-19'504.95
Total EXPENDITURE	-439'799	-310'176

European Society of Hypertension, 6300 Zug

EXPENDITURE

	31.12.2021 (CHF)	31.12.2020 (CHF)
Allowance to the FESH	0 0.0%	0 0.0%
Services sold	↓ -85'924.35	-148'811.20
<i>Various meeting costs</i>	-195.55	-45'961.35
<i>Expenses Meeting Athens</i>	↓ -43'508.00	-102'849.85
<i>Awards granted</i>	-42'220.80	-
Other operating expenses	↑ -271'205.15	-131'878.71
<i>Administrative costs</i>	↑ -72'488.20	-25'990.85
<i>Legal- and professional fees</i>	-36'260.01	-49'715.91
<i>Subscriptions Journal of Hypertension</i>	↑ -110'753.60	-21'968.45
<i>expenses Webinars</i>	-17'409.76	-
<i>other expenses</i>	-2'044.25	-6'749.85
<i>Bank charges</i>	↑ -16'912.33	-7'948.70
<i>Website expenses</i>	-15'337.00	-19'504.95
Financial expenses	↑ -76'462.83	-24'086.25
<i>Loss on securities</i>	↑ -22'235.00	-3'098.00
<i>Loss on currency exchange</i>	↑ -54'227.83	-20'988.25
Total EXPENDITURE	-439'799	-310'176


European Society of Hypertension, 6300 Zug

Report of the statutory auditors
on the limited statutory examination to the General Meeting of
European Society of Hypertension

	Notes	2021	2020
Equity			
Society capital		536'044.99	536'044.99
Retained earnings		1'317'823.95	1'277'221.30
Net result for the year		142'488.38	40'602.65
Total Equity		1'996'357.32	1'853'868.94

European Society of Hypertension, Zug

Balance sheet as at 31 December 2021
(in Swiss francs) x 1000



A medical doctor pretending to be an accountant



THANKS

3.b FESH Financial Report (M. Burnier)

Balance sheet as at 31 December
(in Swiss francs)

Assets	Notes	2021	2020
Current assets			
Cash and cash equivalents		461'791.23	505'943.41
Short-term investments with a quoted market price		40'754.00	40'859.00
<i>Securities (cost price)</i>		58'334.00	58'334.00
<i>Valuation on securities</i>		-17'580.00	-17'475.00
Other current receivables		18'313.55	21'073.55
<i>due from third parties</i>		18'313.55	21'073.55
Accrued income and prepaid expenses		2'760.00	-
Total current assets		523'618.78	567'875.96

CHF	2021	2020
UBS AG, Zürich (CHF)	961.85	297.72
UBS AG, Zürich (USD)	1'258.24	1'115.84
UBS AG, Zürich (EUR)	459'571.14	504'529.85
Total cash	461'791.23	505'943.41

**Profit and loss statement for the financial year
ended 31 December**

(in Swiss francs)

	Notes	2021	2020
Net proceeds from services		-	32'577.00
<i>Subscriptions of Organisations</i>		-	32'577.00
Other operating expenses		-26'467.23	-18'571.19
<i>Administrative costs</i>		-20'783.76	-15'903.91
<i>Legal- and professional fees</i>		-3'286.50	-
<i>Bank charges</i>		-2'396.97	-2'667.28
Financial income		657.80	230.60
<i>Dividend and interest on securities</i>		657.80	230.60
Financial expenses		-20'197.25	-10'701.45
<i>Loss on securities</i>		-105.00	-814.00
<i>Loss on currency exchange</i>		-20'092.25	-9'887.45
Net result for the year		-46'006.68	3'534.96

4. ESH Business Matters

- 4.a Update of ESH By-Laws (R. Kreutz)
- 4.b Election of new Council Members in 2022 (R. Kreutz)
- 4.c New Auditors for ESH and ESH Foundation (R. Kreutz, J. Polonia, M. Burnier)
- 4.d ESH letterhead (R. Kreutz)

4.a Update of ESH By-Laws (R. Kreutz)

By-Laws Task Force members are:

- Giuseppe Mancia
- Andrzej Januszewicz
- Empar Lurbe
- Reinhold Kreutz

4.a Update of ESH By-Laws (R. Kreutz)

- New structure will be implemented (see next slides)

BY-LAWS

ARTICLE I

Name

The name of this organization shall be the European Society of Hypertension

ARTICLE II

Purpose

The objectives of the Society shall be to promote and encourage the advancement of scientific research and knowledge in hypertension. It shall also be to promote and encourage application of the knowledge to medical care in all aspects of hypertension and associated cardiovascular disease. Specifically:



BY-LAWS

English Version

ARTICLE 1 General Information

- § 1 Name, Registered Office and Fiscal year
- § 2 Duration of the society
- § 3 Purpose

ARTICLE 2 Membership

- § 4 Who can be ESH Member
- § 5 Membership Application
- § 6 Membership Categories
- § 7 Membership – Standard Fee
- § 8 Membership – Reduced Fee
- § 9 Honorary Membership
- § 10 Corporate Membership
- § 11 Termination of Membership

ARTICLE 3 Privileges and Duties of Members

- § 12 Privileges of Members
- § 13 Membership Dues

ARTICLE 4 Governing Bodies and Institutions of ESH

- § 14 Governing Bodies and Institutions of ESH
- § 15 ESH Scientific Council
 - a) Composition of ESH Scientific Council
 - b) Election of ESH Scientific Council
 - c) Duties of ESH Scientific Council
 - d) Office Bearers
 - e) Ex-Officio Members
 - f) Executive Officers
 - g) Minutes of Scientific Council Meetings

- § 16 General Assembly
- § 17 Audit
- § 18 Awards Committee

ARTICLE 5 Final provisions

- § 19 Amendments to By-Laws
- § 20 Council Resolutions
- § 21 Cooperation

ARTICLE 1

GENERAL INFORMATION

§ 1 Name, Registered Office and Fiscal year

The name of the organization is the European Society of Hypertension and the abbreviation ESH is used in this document to refer to this organization. The ESH is a society according to Art. 60 et seq. of the Swiss Civil Code. Its seat is in Zug, Switzerland.

The fiscal year of the Society shall be the calendar year.

§ 2 Duration of the Society

The duration of the ESH is undetermined.

§ 3 Purpose

The objective of the Society is the promotion of scientific research, knowledge and education in hypertension and associated diseases. This includes specifically:

1. The ESH will encourage, promote, endorse or organize high quality international scientific activities and communications of the results. Such activities shall be carried out primarily by an annual European Meeting as well as through the organization, participation and co-organization of special scientific and educational meetings worldwide. They shall also be carried out by means of special publications. Research projects may be sponsored or conducted under the special circumstances appropriate to international scientific bodies.
2. The ESH will encourage, promote, endorse or organize activities involved with continuing medical education in the field of hypertension and associated diseases. This will be done also in conjunction with other scientific societies and members of health care professionals.
3. The ESH will encourage, promote, endorse or organize, alone or in conjunction with other scientific societies and members of health delivery professions, postgraduate training and international exchange of investigators, teachers, fellows and students.
4. The ESH supports a Foundation (FESH) in order to achieve its purpose, especially but not limited to grant financial assistance for educational and research purposes. The ESH shall donate to FESH any surplus which are not necessary for achieving its purpose.

ARTICLE 2

MEMBERSHIP

§ 4 Who can be ESH member

Membership in the ESH is open to physicians and any health-care professionals worldwide who are dedicated to research in hypertension, or prevention and treatment (management) of hypertension and associated diseases. The membership of other professions is not excluded in principle and may be granted in individual cases after assessment by the ESH Scientific Council.

§ 5 Membership Application

Applicants are required to apply online at the website of the ESH and are requested to provide:

- A short curriculum vitae (CV) in English (listing academic degrees and professional positions);
- Bibliography of publications related to hypertension and associated diseases;

Letters of endorsement are not required.

Approval of memberships are officially confirmed during the Annual Meeting of the ESH.

§ 6 Membership Categories

The following membership categories are installed:

- Membership: standard fee
- Membership: reduced fee
- Honorary Membership
- Corporate Membership

§ 7 Membership – Standard Fee

Individuals that wish to support and promote the goals of the Society (see § 4) may become standard members with all privileges and duties.

This membership includes two categories:

- With subscription to the online version of the Journal of Hypertension
- Without subscription to the online version of the Journal of Hypertension

§ 8 Membership – Reduced Fee

ESH Young Fellows, other healthcare professionals (e.g., nurses) and professionals from low-income countries may apply for membership with reduced fee and without online subscription to the Journal of Hypertension. These members are eligible for all privileges and duties of ESH membership.

§ 9 Honorary Membership

Individuals who have made extraordinary contributions to research in hypertension or who have given exceptionally important support to the activities of the ESH may be nominated as Honorary Members. Nominations will be considered by the Awards Committee which will bring recommendations to the Scientific Council.

This distinction is limited to a very select group of individuals, and normally no more than one (at most two) Honorary Member(s) are appointed at each Annual Scientific Meeting. Honorary Members will be exempted from annual fees. The subscription to the online version of the Journal of Hypertension is not included in this membership category.

§ 10 Corporate Membership

Institutions or companies interested in the support of hypertension research or management may become corporate members. Each corporate member has one vote at the General Assembly.

§ 11 Termination of Membership

Membership shall cease automatically upon failure to pay the annual fee for one year.

ARTICLE 3

PRIVILEGES AND DUTIES OF MEMBERS

§ 12 Privileges of Members

ESH members participate in the scientific and business sessions of the ESH.

Only members residing in Europe or from ESH affiliated National Hypertension Societies are eligible to vote in the General Assembly during the Annual Scientific Meeting. This also applies to eligibility for election to the ESH Scientific Council.

§ 13 Membership Fees

ESH members shall pay annual fees, in the amount determined by the ESH Scientific Council and approved by the General Assembly of the ESH - either for a Membership with standard or reduced fees. Under the Membership with standard fees, ESH members may choose whether or not to subscribe to the online version of the Journal of Hypertension.

ARTICLE 4

GOVERNING BODIES AND INSTITUTIONS OF ESH

Overview

§ 14 Governing Bodies and Institutions of ESH

The governing bodies and institutions of ESH are:

- ESH Scientific Council
- General Assembly
- Audit
- Awards Committee

§ 15 ESH Scientific Council

The Scientific Council of the ESH is the executive organ of the ESH. The Scientific Council has the duty of supervising all affairs of the ESH. While membership in the ESH is open to applicants worldwide, only ESH members who are European residents are eligible to become a Scientific Council member.

§ 15.a Composition of ESH Scientific Council

The ESH Scientific Council is formed by 11 elected voting members (including Office Bearers), by non-voting ex-officio members and by non-voting Executive officers nominated by the Scientific Council for specific matters.

§ 15.b Election of ESH Scientific Council

ESH Scientific Council members shall be elected as follows: at the time of the General Assembly during the Annual Scientific Meeting of the ESH, the Society shall vote on membership of the ESH Scientific Council for the succeeding four years, giving due consideration to the recommendations of the existing Scientific Council. Any member of the Society may nominate a candidate by writing to the Secretary of the ESH Scientific Council not less than sixty days before the scheduled Annual Scientific Meeting of the ESH.

Members of the Scientific Council may serve for a four-year term with the possibility for an additional four-year term depending on the confirmation by the General Assembly.

§ 15.c Duties of ESH Scientific Council

The presence of six elected members of the ESH Scientific Council constitutes a quorum.

The ESH Scientific Council should normally meet at least twice a year. Meetings should be convened by the ESH President. Additional individuals may be invited by the President to participate at an ESH Scientific Council meeting.

Any group of six Scientific Council members may request the President in writing to convene an extraordinary additional meeting of the ESH Scientific Council provided requests are motivated by valid reasons.

The Secretary of the Society shall inform all ESH Council members of the agenda of the ESH Scientific Council meeting at least 14 days before the meeting is held. Council members may request the President in writing to include additional items in the agenda at least 7 days before the ESH Scientific Council meeting.

§ 15.d Office Bearers

Office Bearers of the Society are:

- the President,
- Immediate Past President,
- the Vice-President,
- the Secretary,
- the Treasurer and,
- the Officer at Large.

Candidates for Office Bearer positions are selected among the elected members of the ESH Scientific Council. They are officially elected by the society members at the time of the General Assembly during the Annual Scientific Meeting, giving due consideration to the recommendations of the ESH Scientific Council.

The President shall serve for a two-year term and shall subsequently remain in the ESH Scientific Council as Office Bearer for two more years as Immediate Past President. This applies also when the total period of the Immediate Past President in the Scientific Council exceeds eight years.

The Vice-President shall normally serve for two years with the possibility for an additional two-year term, but without extension of a maximum eight-year term in the Scientific Council.

The Secretary, the Treasurer and the Officer at Large shall normally serve for two years with the possibility for an additional two-year term, but without extension of a maximum eight-year term in the Scientific Council.

§ 15.e Ex-Officio Members

Ex-Officio non-voting members of the Scientific ESH Council are:

- One ESH member designated by the International Society of Hypertension
- One ESH member representing FESH
- One ESH member representing the affiliated and associated National Hypertension Societies

The ex-officio member shall serve for a two-year term with the option to prolong this term for additional two-year periods.

§ 15.f Executive Officers

The ESH Scientific Council may appoint Executive Officers with specific responsibilities in areas that are regarded by the ESH Scientific Council to require expert attention and decisions on a continuous basis. They can be selected from among ESH Scientific Council members or regular ESH members on account of experience and competence. Executive Officers selected from regular ESH members may be invited by the ESH President to attend the ESH Scientific Council meeting or a portion of the meeting. Areas to be considered for Executive Officer appointments are:

- Coordination of Working Group activities
- ESH Summer Schools
- Educational, research, and communication activities of the Society
- Liaison with other National or International Hypertension Societies or Scientific Bodies

§ 15.g Minutes of Scientific Council Meetings

Minutes, containing all resolutions that have been passed, shall be kept at every meeting of the ESH Scientific Council. The minutes must be signed by the President and the Secretary of the Society and shall be available for inspection by all Scientific Council members at the dedicated Council section at the ESH website.

§ 16 General Assembly

The Society will organize one Annual Scientific Meeting every year. At each Annual Scientific Meeting, a General Assembly shall take place.

The agenda for the General Assembly will be circulated among the ESH Scientific Council and the ESH members at least eight weeks prior to event. Only topics listed in the agenda may be brought up for discussion or vote. Any individual member's request to include items in the agenda must be addressed to the President in writing at least six weeks before the General Assembly is to meet.

Only members residing in Europe or from ESH affiliated National Hypertension Societies are eligible to vote in the General Assembly during the Annual Scientific Meeting.

§ 17 Audit

On the recommendation of the ESH Scientific Council and with the approval of the General Assembly, the Society shall employ an accounting company to prepare and distribute an annual review of the finances of the Society and to provide such other services as deemed necessary by the ESH Scientific Council, the President and the Treasurer.

§ 18 Awards Committee

This Committee will be established in the preparation of the Annual Scientific Meeting each year during the corresponding Scientific Council meeting. It will be chaired by the President of the Society (or a delegate nominated by him/her from among the Scientific Council members), the Vice-President, the Secretary of the Society, the President/Chair of the upcoming Annual Meeting and three other members nominated by the Scientific Council.

This Committee will review the availability and the financial support of ESH Awards for each year. The Committee evaluates the Award candidates proposed by the Scientific Council and ESH members and selects the most appropriate awardees. It also selects individuals eligible for appointment as ESH Honorary Members.

ARTICLE 5

FINAL PROVISIONS

§ 19 Amendments to By-Laws

Amendments to the by-laws of the ESH must be proposed in writing to the ESH Scientific Council by six or more members not less than ninety days before a General Assembly. The agenda of which shall contain an announcement of the proposed amendment. Such amendments require for their adoption an affirmative vote of two-thirds of those present at the General Assembly. A postal vote may be held at the discretion of the ESH Scientific Council. The amendment shall become an active part of the by-laws immediately after the end of the Annual Scientific Meeting or after completion of the postal vote.

§ 20 Council Resolutions

Separately from the by-laws the ESH Scientific Council should maintain a schedule of formal Council resolutions that will help guide its processes. These will include resolutions in the following areas:

1. Guidelines for Conduct of Satellites
2. Arrangements for Annual Scientific Meeting
3. Arrangements for Visiting Faculty
4. Procedures for accord official ESH endorsement of Scientific Meeting in the field of Hypertension
5. Agreements with the Publishers of Scientific Journals
6. Arrangements for elaboration of Guidelines on Hypertension by the Society alone or in cooperation with other Societies and bodies.

§ 21 Cooperation

The Society shall seek to coordinate its activities with other similar Scientific Societies in other parts of the world.

4.a Update of ESH By-Laws (R. Kreutz)

- By-Law changes in detail

Membership Categories

Completely new paragraphs

§ 6 Membership Categories

The following membership categories are installed:

- Membership: standard fee
- Membership: reduced fee
- Honorary Membership
- Corporate Membership

§ 7 Membership – Standard Fee

Individuals that wish to support and promote the goals of the Society (see § 4) may become standard members with all privileges and duties.

This membership includes two categories:

- a) With subscription to the online version of the Journal of Hypertension
- b) Without subscription to the online version of the Journal of Hypertension

§ 8 Membership – Reduced Fee

ESH Young Fellows, other healthcare professionals (e.g., nurses) and professionals from low-income countries may apply for membership with reduced fee and without online subscription to the Journal of Hypertension. These members are eligible for all privileges and duties of ESH membership.

Membership Categories

Slightly amended membership category: „adjusted wording“

previously

5. **Honorary ESH Member**

Individuals who have made extraordinary contributions to research in hypertension or who have given exceptionally important support to the activities of the ESH may be nominated as Honorary Members. Nominations will be considered by the Awards Committee which will bring recommendations to the Scientific Council.

This distinction will be limited to a very select group of individuals, and normally no more than one honorary member will be nominated at any one Scientific Meeting. Honorary members will be exempted from annual dues but not from subscription costs to the official Journal of the ESH.

now

§ 9 **Honorary Membership**

Individuals who have made extraordinary contributions to research in hypertension or who have given exceptionally important support to the activities of the ESH may be nominated as Honorary Members. Nominations will be considered by the Awards Committee which will bring recommendations to the Scientific Council.

This distinction is limited to a very select group of individuals, and normally no more than one (at most two) Honorary Member(s) are appointed at each Annual Scientific Meeting. Honorary Members will be exempted from annual fees. The subscription to the online version of the Journal of Hypertension is not included in this membership category.

↑
Online version of JH +
max 2 per year

Privileges & Duties of Members

previously

6. Rights and Privileges of ESH members

ESH members participate in the scientific and business sessions of the ESH and vote at the General Assembly during the Annual Meeting. ESH members shall be eligible for election to the ESH Scientific Council.

3. ESH members shall pay annual dues, in the amount determined by the ESH Scientific Council and approved by the General Assembly of the ESH. ESH members shall subscribe to the official Journal of the ESH.

now

§ 12 Privileges of Members

ESH members participate in the scientific and business sessions of the ESH.

Only members residing in Europe or from ESH affiliated National Hypertension Societies are eligible to vote in the General Assembly during the Annual Scientific Meeting. This also applies to eligibility for election to the ESH Scientific Council.

§ 13 Membership Fees

ESH members shall pay annual fees, in the amount determined by the ESH Scientific Council and approved by the General Assembly of the ESH either for a Membership with standard or reduced fees. Under the Membership with standard fees, ESH members may choose whether or not to subscribe to the online version of the Journal of Hypertension.

Voting rights



New membership categories added



Office Bearers

previously

5. Office bearers

Office bearers of the Society are: the President, the Vice-President, the Secretary, the Treasurer and the Officer at Large. They are elected by the Society from the elected members of the ESH Scientific Council whose term is continuing for at least two further years. Office bearers are elected at the time of the General Assembly during the Annual Meeting, giving due consideration to the recommendations of the ESH Scientific Council. The President shall serve for a two-year term and shall subsequently remain in the ESH Scientific Council for two more years as immediate Past-President. The Vice-President shall normally serve for two years.

now

§ 15.d Office Bearers

Office Bearers of the Society are:

- the President,
- Immediate Past President,
- the Vice-President,
- the Secretary,
- the Treasurer and,
- the Officer at Large.

Candidates for Office Bearer positions are selected among the elected members of the ESH Scientific Council. They are officially elected by the society members at the time of the General Assembly during the Annual Scientific Meeting, giving due consideration to the recommendations of the ESH Scientific Council.

The President shall serve for a two-year term and shall subsequently remain in the ESH Scientific Council as Office Bearer for two more years as Immediate Past President. This applies also when the total period of the Immediate Past President in the Scientific Council exceeds eight years.

The Vice-President shall normally serve for two years with the possibility for an additional two-year term, but without extension of a maximum eight-year term in the Scientific Council.

The Secretary, the Treasurer and the Officer at Large shall normally serve for two years with the possibility for an additional two-year term, but without extension of a maximum eight-year term in the Scientific Council.

Terms

General Assembly

previously

ARTICLE V

Meetings

The Society will usually convene one General Scientific Meeting every year. At each General Scientific Meeting, a General Assembly shall take place.

At each General Scientific Meeting, the ESH Scientific Council, and one or more auditors. The General Assembly shall be held at the time of the Annual scientific meeting of the Society. Only topics listed in the Agenda may be brought up for discussion or vote. Any individual member's request to include items in the Agenda must be addressed to the President at least six weeks before the General Assembly is to meet.

now

§ 16 General Assembly

The Society will organize one Annual Scientific Meeting every year. At each Annual Scientific Meeting, a General Assembly shall take place.

The agenda for the General Assembly will be circulated among the ESH Scientific Council and the ESH members at least eight weeks prior to event. Only topics listed in the agenda may be brought up for discussion or vote. Any individual member's request to include items in the agenda must be addressed to the President in writing at least six weeks before the General Assembly is to meet.

Only members residing in Europe or from ESH affiliated National Hypertension Societies are eligible to vote in the General Assembly during the Annual Scientific Meeting.

Added timeline



Voting rights



4.b Election of new ESH Council Members 2022 (R. Kreutz)

- Elected Council Members, new President
- Ex-Officio Members
- Executive Officers

Elected Council Members: New President

Currently	Comments
Reinhold Kreutz	until June 2024, continues as Immediate Past President
Empar Lurbe	until June 2023 (2nd term)
Andrzej Januszewicz	until June 2025 (2nd term)
Jorge Polonia	until June 2025 (2nd term)
Konstantinos Tsioufis	term as Immediate Past President ends June 2022
Bojan Jelakovic	term ends June 2022
Michel Azizi	term ends June 2022
Guido Grassi	until June 2027 (2nd term)
Thomas Kahan	until June 2023
Thomas Weber	until June 2027
Bryan Williams	steps down



Candidate: Michalis Doumas



Candidate: Alexandre Persu



Candidate: Atul Pathak






Becomes Officer-at-Large



Candidate: Christian Delles

Ex-officio Members

Currently	Comments
Claudio Borghi	ISH Representative  Will continue
Michel Burnier	FESH Representative  Will continue
Maria Dorobantu	Representative of the National Societies  NEW: Zoltán Jarai

Executive Officers

Currently	Comments
Giuseppe Mancia	
Jana Brguljan	
Dragan Lovic	
Gianfranco Parati	
Philippe Van de Borne	
Enrico Agabiti Rosei	
Antonio Coca	
Athanasios Manolis	
Alexandre Persu	Becomes elected Council Member; remains WG Coordinator
Jan Danser	NEW: Coordinator of ESH Young Fellows Program

4.c New Auditors for ESH and FESH (R. Kreutz, M. Burnier)

- Former auditing company, PricewaterhouseCoopers (PwC), withdraw from contract due to workload (lack of staff) and prizing matters
- Ornitag requested 3 companies to send a proposal: Balmer Etienne, BRISE, Fidelys
- After evaluation of proposals by ESH/FESH treasurers, ESH President and the advisory of Ornitag, we selected BRISE
- The reasons for that decision are:
 - Fair prizing
 - Well known by Ornitag
 - BRISE could conduct the audit on the premisses of Ornitag - everything can be discussed in person; no document sending → easy handling

4.d ESH Letterhead (R. Kreutz)

Address: European Society of Hypertension (ESH), c/o Hausheer & Partner RA, Bahnhofstrasse 10, 6301 Zug, Switzerland | www.eshonline.org
Contact: eshcoordinator@eshonline.org | Twitter: @eshhypertension | Commercial Registry No. CHE-109.819.840

Dear Professor Achenbach,

We are writing you today in response to your last letter dated May 11, 2022. As evident from our first letter of intent sent to you on October 14 in 2021, in which we aimed to explore with you the perspectives for the next version of our joint guidelines for the management of arterial hypertension, we surely have been interested to continue our successful collaboration with ESC in the development of «Joint Guidelines».

However, to our great disappointment, the ESC wishes to discontinue this successful joint effort, as evidenced by the four letters we have received from you between January 5 and May 11 in 2022.

We are aware that despite the fact that in 2016, under the leadership of Professor Fausto Pinto as ESC President, we had established a non-terminated general agreement, the minutes of which have been forwarded to you, the ESC insists to discontinue this previous agreement.

We also reminded you, that European hypertension guidelines were originally initiated by ESH in 2003 and developed without ESC involvement. Only after completion of the guidelines and at the invitation of ESH, ESC accepted to be involved but without ESC-nominated members in the writing committee and without publication in the European Heart Journal, which started in 2007.

Instead of continuing this successful joint effort, the ESC invited the ESH in response to our letter of intent from October 2021, to develop the next guidelines for the management of arterial hypertension “in collaboration” (rather than jointly). Furthermore, without consulting with ESH and before we had a chance to reply to your first response letter in January 2022, ESC predetermined the publication year and already disseminated their call for participation in the ESC Guidelines Task Force for Arterial Hypertension in 2024. You also informed us, that ESH will be represented by «only» three Task Force members and three reviewers in these guidelines.

5. ESH/ESC Hypertension Guidelines (G. Mancia, R. Kreutz)

This email invite to join the Task Force for the establishment of the GL was sent to all ESH Council Members and Officers and selected other experts on May 30, 2022:

As you know, following our Baveno Meeting in September 2021, we discussed the development of future European Hypertension Guidelines for the Management of Hypertension with the European Society of Cardiology (ESC). In our ESH letter of intent to the ESC President (S. Achenbach) in October 2021, we suggested - after our successful collaboration in previous years including the generation of the current 2018 ESC/ESH Guidelines - to continue our work together with the ESC Task Force on this topic.

However, as presented and discussed during our ESH Council meeting on January 29 this year, ESC (President, S. Achenbach) responded to us on January 5, 2022, and indicated that ESC will not continue to develop «Joint Guidelines» with ESH but rather invited us to develop the next guidelines for the management of arterial hypertension “in collaboration”. In the second week of January, without consulting with ESH and before we had the chance to send our response to the letter from January 5, ESC already published and disseminated their call for participation in the ESC Guidelines Task Force for Arterial Hypertension.

Subsequently, ESH sent two response letters to ESC (January 21, March 15) stating our position and our suggestion to continue developing «Joint Guidelines» based on our 2016 agreement with ESC with a similar contribution of ESH and ESC. In three follow up letters, the ESC responded with essentially the same message, insisting on its position with three important conditions:

1. *The guidelines will be developed by the ESC and the title will read: “in collaboration with ESH.”*
2. *The ESH will be represented by **three Task Force members and three reviewers**. Participating ESH authors and reviewers can be appointed by the ESH but must comply with ESC DOI and participation rules.*
3. *Furthermore, publication and presentation of the document will be done at the ESC congress, while the ESH may only present a preview presentation of the guidelines during its annual congress, but subject to the fulfillment of certain conditions as judged by ESC regulations.*

This is very unfortunate, but based on three letters, all signed by the ESC President (S. Achenbach), the position of the ESC seems very clear and unacceptable to ESH.

This has two consequences for ESH:

1. ESH is forced to develop its own guidelines, on the one hand to ensure the quality of the hypertension guidelines through participation of a broad spectrum of hypertension experts, and on the other hand to document the original authorship of the guidelines, which lies with the ESH.
2. An additional contribution by ESH to the ESC 2024 guidelines «in collaboration» with the participation of three ESH-appointed Task Force members is not reasonable.

In this regard, we would like to invite you to become a «Member of the ESH Task Force for the ESH Guidelines for the Management of Arterial Hypertension»

Please note, that **any member of the ESH Task Force cannot simultaneously participate in the ESC Task Force for the 2024 ESC Guidelines on Arterial Hypertension. Accordingly, we expect each appointed member of the ESH Task Force to provide written confirmation via reply email.**

We would be very happy and grateful if you would agree and send us your response until **Monday, June 6.**

With kind regards

Reinhold Kreutz
ESH President

Giuseppe Mancia
Chair of the ESH Hypertension Guidelines Task Force

5. ESH/ESC Hypertension Guidelines (G. Mancia, R. Kreutz)



6. ESH Official Journals (R. Kreutz, M. Burnier)

6.a Journal of Hypertension (R. Kreutz)

- Status of new contract

6.b Blood Pressure (M. Burnier)

6.a Journal of Hypertension (R. Kreutz)

Status of new contract

- Re-negotiation process is still ongoing

Already agreed topic

- ESH membership without subscription to the Journal of Hypertension

Ongoing negotiations on the following topics

- Royalties – marginally increased 0.25% to 7.5%

6.b Blood Pressure (M. Burnier)

General update

7. ESH Clinical Update & News (G. Grassi, R. Kreutz)

Volume 1

BLOOD PRESSURE
2022, VOL. 31, NO. 1, 118–120
<https://doi.org/10.1080/08037051.2022.2075826>

Taylor & Francis
Taylor & Francis Group

ESH CLINICAL UPDATE AND NEWS

OPEN ACCESS 

Hypertension in older patients: a STEP forward?

Athanase Benetos^a, Alexandre Persu^b and Reinhold Kreutz^c

^aGeriatric Department, University Hospital of Nancy, Université de Lorraine, Nancy, France;
^bDivision of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium;
^cCharité – Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany

ESH Editor
Guido Grassi, Milan

ESH Co-Editors:
Rosa Maria Bruno, Paris
Georg Ehret, Geneva

ARTICLE HISTORY Received 5 May 2022; Accepted 6 May 2022

Context

Recently, interesting novel data on the target blood pressure (BP) for treatment in older patients with hypertension were reported by the STEP (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients) study investigators [1].

Discussion


STEP is a randomised controlled trial (RCT) conducted in China that randomised 8,511 patients in a 1:1 ratio to either a target systolic BP (SBP) corridor between 110 mmHg and 130 mmHg (intensive treatment group) or a corridor between 130 and 150 mmHg (standard

Volume 2

BLOOD PRESSURE
2022, VOL. 31, NO. 1, 121–124
<https://doi.org/10.1080/08037051.2022.2077698>

Taylor & Francis
Taylor & Francis Group

ESH CLINICAL UPDATE AND NEWS

OPEN ACCESS 

Mild chronic hypertension in pregnancy: to treat or wait?

Costas Thomopoulos^a, Jana Brguljan^b, Renata Cifkova^{c,d}, Alexandre Persu^e and Reinhold Kreutz^f

^aDepartment of Cardiology, Helena Venizelou General & Maternity Hospital, Athens, Greece;
^bHypertension Department, Medical University Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia; ^cCenter for Cardiovascular Prevention, First Faculty of Medicine and Thomayer University Hospital, Charles University in Prague, Prague, Czech Republic; ^dDepartment of Medicine II, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; ^eDivision of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; ^fInstitute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany

ESH Editor:
Guido Grassi, Milan

ESH Co-Editors:
Rosa Maria Bruno, Paris
Georg Ehret, Geneva

ARTICLE HISTORY Received 5 May 2022; accepted 11 May 2022

KEYWORDS Hypertension; women; pregnancy; pre-eclampsia

7. ESH Clinical Update & News (G. Grassi, R. Kreutz)

In the pipeline for 2022:

- a. Coffee and BP
- b. Physical activity in hypertension
- c. Update on BP monitoring devices
- d. Arterial stiffness for HMOD assessment
- e. EMPA-kidney study (SGLT2 inhibitors in CKD)

8. ESH Working Group Activities (A. Persu)

- 8.a Changes in the leadership of the WGs
- 8.b Ongoing / new projects
- 8.c Ongoing / new position papers

8.a Changes in the leadership of the WGs

Blood Pressure Monitoring and Cardiovascular Variability

Chair George Stergiou > Paolo Palatini	Secretary Paolo Palatini > Alejandro de la Sierra
--	---

Device-based Treatment of Hypertension

Chair Roland Schmieder	Vice-Chair Felix Mahfoud	Secretary Kyriakos Dimitriadis
----------------------------------	------------------------------------	--

Diabetes and Metabolic Risk Factors

Chair Vasilios Kotsis	Secretary > Christina Antza (> Chair in 2023)
---------------------------------	---

Endocrine Hypertension

Chair Paolo Mulatero	Secretary > Aleksander Prejbisz (> Chair in 2023)
--------------------------------	---

Hypertension and Cardiovascular Disease in Special Populations

Section: Hypertension in Women	Section: Hypertension in Older Adults	Section: Hypertension in subjects living in or emigrating from low resource settings
Chair Costas Thomopoulos	Chair Athanasios Benetos	Chair Pietro Amedeo Modesti

Hypertension and the Brain

Ongoing Voting Process

Chair Pedro Guimarães Cunha	Vice-Chair Cristina Sierra	Secretary Dagmara Hering
---------------------------------------	--------------------------------------	------------------------------------

8.a Changes in the leadership of the WGs

Hypertension and the Heart

Chair Enrico Agabiti Rosei	Vice-Chair Konstantinos Tsioufis	Secretary Miguel Camafort
--------------------------------------	--	-------------------------------------

Hypertension and the Kidney

Chair Pantelis Sarafidis > Jean-Michel Halimi	Secretary Jean-Michel Halimi Ongoing voting process
---	---

Hypertension in Children and Adolescents

Chair Empar Lurbe > Stella Stabouli	Vice-Chair Stella Stabouli > Dorota Drozd	Secretary Denes Pall
---	---	--------------------------------

Lifestyle, Cardiovascular Pharmacotherapy and Adherence

Chair Michel Burnier > Michel Azizi	1st Vice-Chair Michel Azizi > Veronique Cornelissen	2d Vice-Chair Jorie Versmissen
---	---	---

Large Arteries

Chair Bart Spronck > Rosa Maria Bruno	Vice-Chair Rosa Maria Bruno > Dimitrios Terentes-Printzios	Secretary Rosa Maria Bruno > Elisabetta Bianchini
---	--	---

Small Arteries

Section: Hypertension and Sexual Dysfunction	Section: Microcirculation and Inflammation
Chair Margus Viigimaa	Chair Agostino Virdis

8.b Ongoing projects

Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence



Will be presented during the meeting!

PATIENT PERSPECTIVES ON TREATMENT ADHERENCE IN HYPERTENSION: PRELIMINARY RESULTS OF AN ESH SURVEY IN FIVE COUNTRIES

M. Burnier, A. Persu, M. Azizi, A. Prejbisz, A. Cunha, P. Gupta, J. Vaclavik, J. Versmissen, R. Kreutz, S. Kjeldsen, G. Desideri*.

For the ESH Working Group on Lifestyle, Cardiovascular Therapy and Adherence in collaboration with the Senior International Health Association (SIHA)* and Servier International

8.b Ongoing projects

Working Group on Hypertension and the Kidney

"HAMA" (a cohort of patients with malignant hypertension followed in France)

(R. Boulestreau)

Revisiting malignant hypertension: rationale and design of the "HAMA cohort", **on behalf of the ESH working group "Hypertension and the kidney"**

Authors: Romain Boulestreau^{1,2,3}, Aurélien Lorthioir⁴, Alexandre Persu⁵, Pantelis Sarafidis⁶, Antoine Cremer¹, Pierre-Louis Tharaux⁷, Sebastien Rubin⁸, Alexandre Maier⁹, Mikael Mazighi¹⁰, Michel Paques¹¹, Sophie Bonnin¹¹, Stéphane Debeugny¹², Jean Michel Halimi¹³, Philippe Gosse¹.

Article ready to submit

- **Blood Pressure?**
- **Journal of Hypertension?**

8.b New projects

Working Group on Hypertension in Children and Adolescents

Survey on transition of hypertensive youth from pediatric to adult care units among ESH Excellence Centers (E. Lurbe and S. Stabouli)

We propose a survey-based study on transition of hypertensive youth to adult care, to be performed among ESH excellence centers.

The aim of the study is to assess the current status of transition from pediatric to adult care from the adult perspective. Pediatric centers exclusively caring for children and adolescents may also complete this survey but will be also asked to participate in a future questionnaire focused on pediatric aspects.

The current ***22-question survey*** includes two parts:

- A) examining the transition process among centers
- B) assessing clinical practice aspects in the evaluation and management of hypertension and organ damage in adolescents and young adults.

8.b New projects

Working Group on Diabetes and Metabolic Risk Factors

Survey on management of obese hypertensive patients in ESH Excellence Centers

(V. Kotsis and C. Antza)

The aim is to understand the role of lifestyle modifications and advice among the centers of excellence of ESH in obese hypertensive patients.

These data will help us to understand the current practice and to develop new tools for everyday clinical practice for the obesity pandemic and its comorbidities.

8.c Ongoing position papers

Position paper- submitted

Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension

Lead authors: Martin Reincke, Francesco Fallo

Suggested target Journal: *Journal of Hypertension*

8.c Ongoing position papers

Position paper- final phase

BLOOD PRESSURE VARIABILITY: methodological and pathophysiological aspects, clinical relevance and practical indications. A position paper by the ESH Working Group on Blood Pressure Monitoring and Cardiovascular Variability.

Lead authors:

Gianfranco Parati, George Stergiou, Gregorz Bilo....

Suggested target Journal:

Journal of Hypertension

8.c Ongoing position papers

Position paper- in preparation

2022 Guidelines for Validation of Non-invasive Arterial Pulse Wave Velocity Measurement Devices

Update of Wilkinson et al., *Artery Research* 2010; 4:34-40; 2010.

Submitted by : **WG on Large Arteries**

Lead authors:

Bart Spronck, Elisabetta Bianchini, Rosa Maria Bruno, Dimitrios Terentes
Printzios

Endorsed by other entities: ARTERY; COST Action VascAgeNet; others
pending

Suggested target Journals:

Journal of Hypertension and Artery Research

8.c New position paper

Working Group on Large Arteries (also endorsed by **Artery/ ESC Council HTN** - pending)

Topic: Recommendations for the use of pulse wave velocity in clinical practice

Rationale:

To summarize the evidence for using pulse wave velocity in clinical practice

- methodological aspects
- use of PWV in primary prevention, in hypertension, in diabetes
- use of PWV for risk stratification and diagnosis
- use of PWV for treatment guidance
- use of PWV in cardiac diseases such as coronary artery disease, HFpEF
- use of PWV in neurological diseases such as stroke and dementia

Suggested target Journal: Journal of Hypertension + Artery Research


Expected month/year of submission to Journal: Sep/2022

Responsible lead authors: T Weber, B Spronck, RM Bruno, A Protogerou, C. Vlachopoulos

9. Research Projects

- 9.a ESH ABPM Covid-19 Study (A. Januszewicz, T. Weber)
- 9.b „Exposure to Trauma and Hypertension in Ukrainian Refugees“ (A. Persu, M. Burnier)
- 9.c Current and future projects (R. Kreutz)


9.a ESH ABPM Covid-19 Study (A. Januszewicz, T. Weber)




9.b ESH Research Projects

The impact of war-related trauma exposure on development and progression of Arterial Hypertension and Cardiovascular disease in Ukrainian refugees (A. Persu, M. Burnier, K. Narkiewicz).



The impact of war-related trauma exposure on development and progression of Arterial Hypertension and Cardiovascular disease in Ukrainian refugees



SCREENING IN SCHOOLS



N=1000




Office BP



PTSD Screening –
PCL5 Questionnaire

The impact of war-related trauma exposure on development and progression of Arterial Hypertension and Cardiovascular disease in Ukrainian refugees



SCREENING IN SCHOOLS



Office BP



PTSD Screening – PCL5 Questionnaire



Comparison

Normotensive vs. hypertensive subjects

Controlled vs. uncontrolled/resistant hypertensive subjects

The impact of war-related trauma exposure on development and progression of Arterial Hypertension and Cardiovascular disease in Ukrainian refugees



N=200



HTN and PTSD
Management and follow-up



N=200




Pathophysiological
evaluation

ABPM
ECG and Echocardiography
Heart Rate Variability
Pulse Wave Velocity
Hormonal and immune panel
Functional MR


The impact of war-related trauma exposure on development and progression of Arterial Hypertension and Cardiovascular disease in Ukrainian refugees




HTN and PTSD
Management and follow-up



Pathophysiological
evaluation



Comparison of hypertensives with PTSD
and hypertensives without PTSD



Comparison of subjects with PTSD,
Hypertension, both and none of them

The impact of war-related trauma exposure on development and progression of Arterial Hypertension and Cardiovascular disease in Ukrainian refugees




Krzysztof Narkiewicz




Alexandre Persu



Michel Burnier



Anna Shalimova



Elvira Fanelli

9.c Current and future projects (R. Kreutz)

10. Summer School 2022 - Update (J. Brguljan, D. Lovic)

- 10.a Date and location
- 10.b Application situation
- 10.c Program draft
- 10.d Organizational matters (venues, sponsoring etc)

10.a Date & Location (J. Brguljan, D. Lovic)

Date: 17. - 22. September 2022

Venue: Sremski Karlovci, Serbia
Hotel Premier Aqua



10.b Application situation (J. Brguljan, D. Lovic)

58 candidates out of the countries below:

Argentina
Austria
Belgium
Bosnia & Herzegovina
Bulgaria
China
Croatia
Czech Republik
Denmark
France
Germany
Greece
Hungary
Israel
Italy
Latvia
Lithuania
Montenegro (supported by Bosnia & Herzegovina)
The Netherlands
Norway
Poland
Portugal
Romania
Serbia
Slovakia
Slovenia
Sweden
Switzerland
Turkey
United Kingdom

List of countries without candidates

Armenia
Cyprus
Egypt
Estonia
Finland
Georgia
Kazakhstan
Lebanon
Saudi Arabia
Spain
Ukraine

10.c Program Draft (J. Brguljan, D. Lovic)

TOPICS:

- Basic science
- Novelties in hypertension clinics
- How to establish research projects
- How to publish an article
- Transfer findings in daily clinical practice
- Practical workshops

SUMMER SCHOOL 17. - 22. September 2022

	17.09. Saturday	18.09. Sunday	19.09. Monday	20.09. Tuesday	21.09. Wednesday	22.09. Thursday
7.00 - 9.00		Breakfast and some sport activities				
9.00 - 11.00	Arrival all day	Session II	Session IV	Session VI	Session VIII	Session X
12.00 - 14.00		Session III	Session V	Session VII	Session IX	Panel Discussion, Workshop
14.00 - 15.00		LUNCH	LUNCH	LUNCH	LUNCH	LUNCH
15.00 - 16.30		Students Presentations	Students Presentations	WG Presentation	II. Tour, Belgrade	departure
16.30 - 18.00		WG presentation, Practical workshops	WG presentation, Practical workshops	Panel Discussion		
18.00 - 19.30	Session I: How to...	Case Reports	I Tour, visit of near by City	Case reports		
19.30	DINNER					

10.d Organizational matters (J. Brguljan, D. Lovic)

- Sponsoring / financial matters update
- Faculty:
 - Onsite: n = tbd (at least 2 active days; ideally for entire Summer School duration)
 - Virtual n = tbd, Key Lectures (30 min max, students included in discussion appointed in advance)
- Lecturers will be asked to send some materials to students for their preparation for discussion
- Practical workshops

11. Future Summer Schools (R. Kreutz)

According to the minutes of the March 2020 Council meeting, the following countries are responsible for organizing the next ESH Summer Schools:

2023 – Italy (G. Parati)

2024 – France (M. Azizi)

2025 – Sweden (T. Kahan)

2026 – The Netherlands (J. Danser) – *proposal by R. Kreutz*

12. Excellence Centres (T. Weber)

BLOOD PRESSURE
2022, VOL. 31, NO. 1, 71–79
<https://doi.org/10.1080/08037051.2022.2060182>




ORIGINAL ARTICLE

 OPEN ACCESS  Check for updates

Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension

Thomas Weber^a, Jaques Amar^b, Tine de Backer^c , Thilo Burkard^d, Marcus van der Giet^e, Philippe Gosse^f, Andrzej Januszewicz^g, Thomas Kahan^h, Giuseppe Manciaⁱ, Christopher C. Mayer^j, Maria Lorenza Muiesan^k, George S. Stergiou^l, Konstantinos Tsioufis^m, Bernard Vaisseⁿ, Reinhold Kreutz^e and Covid-19 Task Force of the European Society of Hypertension

^aCardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria; ^bDepartment of Hypertension, Toulouse University Hospital, Toulouse, France; ^cCardiovascular Center, Heymans Institute of Clinical Pharmacology, University Hospital Gent, Gent, Belgium; ^dMedical Outpatient Department and Hypertension Clinic, University Hospital Basel, Basel, Switzerland; ^eHypertension Centre Berlin, Charite Universitätsmedizin Berlin, Berlin, Germany; ^fUnité Hypertension Artérielle, University of Bordeaux, Bordeaux, France; ^gDepartment of Hypertension, Institute of Cardiology, Warsaw, Poland; ^hDepartment of Cardiology, Danderyd University Hospital, Stockholm, Sweden; ⁱUniversity of Milano-Bicocca, Milan, Italy; ^jHealth and Bioresources Division, Austrian Institute of Technology, Vienna, Austria; ^kDepartment of Clinical and Experimental Sciences, Centro per la Prevenzione e Cura dell'ipertensione Arteriosa, University of Brescia and ASST Spedali Civili, Brescia, Italy; ^lThird Department of Medicine, Sotiria Hospital, Hypertension Center STRIDE-7, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; ^m1st Cardiology Clinic, National and Kapodistrian University of Athens, Athens, Greece; ⁿService de Rythmologie et d'Hypertension, Pôle Cardiovasculaire et Thoracique, Marseille, France



> [Blood Press.](#) 2022 Dec;31(1):71-79. doi: 10.1080/08037051.2022.2060182.

Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension

Thomas Weber ¹, Jaques Amar ², Tine de Backer ³, Thilo Burkard ⁴, Marcus van der Giet ⁵, Philippe Gosse ⁶, Andrzej Januszewicz ⁷, Thomas Kahan ⁸, Giuseppe Mancina ⁹, Christopher C Mayer ¹⁰, Maria Lorenza Muiesan ¹¹, George S Stergiou ¹², Konstantinos Tsioufis ¹³, Bernard Vaisse ¹⁴, Reinhold Kreutz ⁵, Covid-19 Task Force of the European Society of Hypertension

Affiliations – collapse

Affiliations

- 1 Cardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria.
- 2 Department of Hypertension, Toulouse University Hospital, Toulouse, France.
- 3 Cardiovascular Center, Heymans Institute of Clinical Pharmacology, University Hospital Gent, Gent, Belgium.
- 4 Medical Outpatient Department and Hypertension Clinic, University Hospital Basel, Basel, Switzerland.
- 5 Hypertension Centre Berlin, Charite Universitätsmedizin Berlin, Berlin, Germany.
- 6 Unité Hypertension Artérielle, University of Bordeaux, Bordeaux, France.
- 7 Department of Hypertension, Institute of Cardiology, Warsaw, Poland.
- 8 Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden.
- 9 University of Milano-Bicocca, Milan, Italy.
- 10 Health and Bioresources Division, Austrian Institute of Technology, Vienna, Austria.
- 11 Department of Clinical and Experimental Sciences, Centro per la Prevenzione e Cura dell'ipertensione Arteriosa, University of Brescia and ASST Spedali Civili, Brescia, Italy.
- 12 Third Department of Medicine, Sotiria Hospital, Hypertension Center STRIDE-7, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- 13 1st Cardiology Clinic, National and Kapodistrian University of Athens, Athens, Greece.
- 14 Service de Rythmologie et d'Hypertension, Pôle Cardiovasculaire et Thoracique, Marseille, France.

54 ECs
18 European
3 non-European

Writing group:

Thomas Weber (1), Jaques Amar (2), Tine de Backer (3), Thilo Burkard (4), Marcus van der Giet (5), Philippe Gosse (6), Andrzej Januszewicz (7), Thomas Kahan (8), Giuseppe Mancina (9), Christopher C. Mayer (10), Maria Lorenza Muiesan (11), George S. Stergiou (12), Konstantinos Tsioufis (13), Bernard Vaisse (14), and Reinhold Kreutz (5) (writing group). Covid-10 Task Force of the European Society of Hypertension.

Contributing Excellence Centers:

Ábrahám György (15), Istvan Barna (16), Weimar Kunz Sebba Barroso (17), Miguel Camafort-Babkowski (18), Claude Braun (19), Santina Cottone (20), Kathrin Danninger (1), Georg Ehret (21), Daniel Gordin (22), Guido Grassi (23), Charalampos Grassos (24), Fernando Jaén Águila (25), Zoltan Jarai (26), Klaus Kisters (27), Vasilios Kotsis (28), Jean-Marie Krzesinski (29), Marilucy Lopez-Sublet (30), Dragan Lovic (31), Empar Lurbe (32), Thomas K. Makris (33), Athanasios J. Manolis (34), Maria Marketou (35), Pietro Minuz (36), Jean-Jacques Mourad (37), Edgar Nasr (38), Patricia Van der Niepen (39), Olivier Ormezzano (40), Ioannis Papadakis (41), Jorge Polonia (42), Dimitrios Papadopoulos (43), Dimitar Raev (44), Marek Rajzer (45), Josep Redon (46), Nicolás Roberto Robles (47), Riccardo Sarzani (48), Filippo Scalise (49), Anna Oliveras Serrano (50), Vesna Stojanov (51), Costas Thomopoulos (33), Jan Vaclavik (52), Franco Veglio (53), Margus Viigimaa (54), Jiri Widimski (55), Pantelis Zebekakis (56), Parounak Zelveian (57).

Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension




Figure 1. Reduction in hypertension-related diagnostic tests and one selected therapeutic procedure from 2019 to 2020. Left side:

12. Excellence Centres (T. Weber)



EUROPEAN SOCIETY OF HYPERTENSION

THIS IS TO CERTIFY THAT

*2nd Propedeutic Department of Internal Medicine,
Hippokraton Hospital
Aristotle University of Thessaloniki*

HAS MET THE REQUIREMENTS AND QUALIFIES AS A

Hypertension Excellence Centre

OF THE EUROPEAN SOCIETY OF HYPERTENSION

May, 2022




Prof. Reinhold Kreutz

PRESIDENT



Prof. Andrzej Januszewicz

SECRETARY



Prof. Thomas Weber

EXCELLENCE CENTRE
REPRESENTATIVE

Head: Michael Doumas

APPROVED



EUROPEAN SOCIETY OF HYPERTENSION

THIS IS TO CERTIFY THAT

*Hypertension Centre, Centre for Nephrology,
General Hospital of Nikaia, Piraeus*

HAS MET THE REQUIREMENTS AND QUALIFIES AS A

Hypertension Excellence Centre

OF THE EUROPEAN SOCIETY OF HYPERTENSION

March, 2022



Prof. Reinhold Kreutz

PRESIDENT



Prof. Andrzej Januszewicz

SECRETARY



Prof. Thomas Weber

EXCELLENCE CENTRE
REPRESENTATIVE

Head: Rigas Kalaitzidis

13. ESH GP Network (R. Kreutz)

13. ESH GP Network (R. Kreutz)



ESH GP Network



Rosa de Pinho,
Portugal



Agnieszka
Mastalerz-Migas
Poland

14. ESH Annual Meetings

- 14.a 2022 ESH Annual Meeting, June 17-20, 2022, Athens (K. Tsioufis, R. Kreutz, M. Massaro)
 - ESH Awards 2022 (R. Kreutz)
- 14.b 2023 ESH Annual Meeting, June 23-26, 2023, Milan (G. Mancia, M. Massaro)
- 14.c 2024 ESH Annual Meeting, May 30-June 3, 2024, Berlin (R. Kreutz, M. Massaro)

31st European Meeting on Hypertension and Cardiovascular Protection

June 17-20, 2022
Athens, Greece

Megaron Athens International
Conference Centre (MAICC)



Focus on
hypertension
and
heart failure
phenotypes



www.esh2022.eu

UPDATES JUNE 17, 2022

UPDATED FIGURES

CONGRESS DAYS	4
MEETING ROOMS	7
EDUCATIONAL HOURS	32
CONGRESS SESSIONS	126
ORAL PRESENTATIONS	116
E-POSTERS	779

TOTAL REGISTRATIONS

TOTAL REGISTRATIONS TO THE CONGRESS 3343

IN-PERSON REGISTRATIONS 1569
VIRTUAL REGISTRATIONS 1774

FACULTY 362
IN-PERSON 237
VIRTUAL 123
UNKNOWN 2


GREEK REGISTRATIONS (AIM and AFEA) 882

IN-PERSON 525
VIRTUAL 252

REGISTRATION – TOP 10 COUNTRIES

GREECE	854
INDIA	495
PORTUGAL	213
SPAIN	133
ROMANIA	122
FRANCE	118
ITALY	108
POLAND	80
ARGENTINA	73
TUNISIA	66

REGISTRATIONS - by continents



SPONSORS

PLATINUM

SERVIER

GOLD

MENARINI

MERCK

SILVER

MEDTRONIC

OMRON HEALTHCARE

EUROPE

BRONZE

FERRER

RECOR MEDICAL

SANOFI

SUPPORTERS

AKTIIA

BIOBEAT

TECHNOLOGIES

CUSTO MED

INBODY

KARABINIS MEDICAL

KRKA

NOVACOR

PFIZER HELLAS

SOMNOMEDICS

SPACELABS

HEALTHCARE

UNI-PHARMA

VIANEX

VIATRIS

WIN MEDICA

WISEPRESS

SCIENTIFIC PROGRAMME

Breakfast Workshop	18
Plenary Sessions	6
Workshops	11
Joint Sessions	14
Oral Sessions	27
Working Groups	12
How-To Sessions	6
Meet-The-Experts	5
Teaching Seminars	3
Clinical Case Sessions	7

JOINT SESSIONS

- **Joint Session ESH-WHL (World Hypertension League)**
CALL TO ACTION FOR HYPERTENSION CONTROL IN AFRICA
- **Joint Session ESH- WHO (World Health Organization)**
NONCOMMUNICABLE DISEASES AND MIGRANT HEALTH
- **Joint Session ESH-CHL**
JOINT SESSION ON CENTRAL HAEMODYNAMICS
- **Joint Session ESH-KSH (Korean Society of Hypertension)**
CURRENT CONCEPTS OF HYPERTENSION MANAGEMENT IN YOUNG PATIENTS
- **Joint Session ESH-ERA (European Renal Association)**
CURRENT CONCEPTS IN HYPERTENSION AND KIDNEY DISEASE
- **Joint Session ESH-LASH (Latin American Society of Hypertension)**
THE CHALLENGE OF IMPROVING BLOOD PRESSURE CONTROL
- **Joint Session ESH-Indian Society of Hypertension**
REDUCING CARDIOVASCULAR RISK IN HYPERTENSION
- **Joint Session ESH-HEART FAILURE ASSOCIATION (HFA)**
FROM HYPERTENSION TO HEART FAILURE
- **Joint Session ESH-HSH and Hellenic Society of Internal medicine, Hellenic Atherosclerosis Society and Hellenic Society of Cardiology**
NEW THERAPEUTIC OPPORTUNITIES FOR MANAGEMENT OF HYPERTENSION
- **Joint Session ESH-ISH (International Society of Hypertension)**
NEW THERAPEUTIC OPPORTUNITIES FOR MANAGEMENT OF HYPERTENSION
- **Joint Session ESH-ESC (European Society of Cardiology)**
HYPERTENSION AND ORGAN DAMAGE
- **Joint Session ESH-ARTERY Society**
ARTERIAL BIOMARKERS IN CLINICAL HYPERTENSION: HOW TO MOVE EVEN FURTHER?
- **Joint Session ESH-ACC (American College of Cardiology)**
HOME BLOOD PRESSURE MONITORING- AMERICAN AND EUROPEAN PERSPECTIVES AND FUTURE DIRECTIONS
- **Session Jointe ESH et Société d'Hypertension de Langue Française - Joint Session ESH and French speaking Hypertension Societies** - HOME NOUVEAUTÉS DANS LE DOMAINE DE L'HYPERTENSION - INNOVATION IN HYPERTENSION

SPONSORED SESSIONS

CONFIRMED SESSIONS:

AKTIIA	1 hands-on
MEDTRONIC	1 minisymposium
MENARINI GROUP	1 minisymposium
MERCK	1 satellite symposium
OMRON HEALTHCARE	1 minisymposium
PFIZER HELLAS	1 lecture
RECOR MEDICAL	1 minisymposium
SANOFI	1 minisymposium (educational grant)
SERVIER	1 satellite symposium + 2 minisymposia
SOMNOMEDICS	1 hands-on

**TOTAL N. 12 SPONSORED
SESSIONS**

12 @ESH2019

20 @ESH-ISH2021



OTHER SPONSORSHIP



EXHIBITION AREA TOT. 344 SQM | 22 BOOTHS

2 DIGITAL PACKAGES

5 EMAIL BLAST

6 PUSH NOTIFICATIONS ON EVENT APP

1 PROMOTIONAL VIDEO

1 INTERVIEW

1 SURVEY

2 LIVE POLLING

2 ADV PAGES IN THE FINAL PROGRAMME

1 COMPANY LOGO IN THE PLATFORM HOMEPAGE

FACULTY MEMBERS BY COUNTRY

GREECE	77
ITALY	31
UNITED KINGDOM	25
USA	21
GERMANY	20
FRANCE	17
SPAIN	17
POLAND	14
THE NETHERLANDS	11
AUSTRALIA	7
BELGIUM	7
ROMANIA	7
CROATIA	6
PORTUGAL	6
SWITZERLAND	6
CHINA	5
SWEDEN	5
JAPAN	4
SOUTH KOREA	4
ISRAEL	4
AUSTRIA	4

CYPRUS	4
CZECH REPUBLIC	4
NORWAY	4
SERBIA	4
CANADA	4
INDIA	3
BULGARIA	3
HUNGARY	3
LITHUANIA	3
TURKEY	3
KENYA	2
NIGERIA	2
SOUTH AFRICA	2
IRELAND	2
SLOVENIA	2
RUSSIA	2
BRAZIL	2
CAMEROON	1
TUNISIA	1
HONG KONG	1
ARMENIA	1

ARMENIA	1
SAUDI ARABIA	1
IVORY COAST	1
DENMARK	1
ESTONIA	1
FINLAND	1
SLOVAK REPUBLIC	1
BOSNIA AND HERZEGOVINA	1
MONACO	1
MONTENEGRO	1
ARGENTINA	1
COLOMBIA	1

ABSTRACTS

RECEIVED AT FIRST DEADLINE	839
LATE BREAKERS	94
TOTAL RECEIVED	933
Rejected Abstracts	0
Withdraw Abstracts	39
ORAL PRESENTATIONS included in the programme	116
E-POSTERS included in the programme	779

AWARDS

Björn Folkow Award

Costas Thomopoulos

Alberto Zanchetti Life Achievement Award

Patricio López-Jaramillo

ESH Honorary Membership

Venkata S. Ram

Bonita Falkner

Talal Zein Awards

Dennis Bernieh

Evangelos Ntalianis

Joonatan Palmu

Yuliya Repchuk

Marta Sanz-Gómez

Barbara Verhaar

Paul Milliez Award

Philippe Gosse

Hybrid Mode Specs & Features

The experience from the last year has shown us that to reach a larger number of members and interested specialists, the European Society of Hypertension needs to adopt a flexible way to deliver the ESH Annual Meeting content.

Following the main purpose of providing a stable and organised European platform for scientific exchange in hypertension, the 2022 Annual Meeting will be held in hybrid format.

Participants will have access to:	In- person mode	Online mode
Scientific sessions: Plenaries, Joint Sessions, Topical Workshops, Breakfast Workshops, Oral Communications, Working Groups, Meet the expert Sessions, How-to Sessions	✓	✓
Industry sessions	✓	✓
Exhibition	✓	
E-Posters	✓	✓
Online LIVE platform		✓
3 months on-demand contents (until September 20, 2022)	✓	✓
Certificate of attendance	✓	✓
Box lunches (Saturday, Sunday, Monday)	✓	
Congress material	✓	
Abstract book online	✓	✓
Interaction and networking	✓	✓

GREEN MEETING

WE GO GREEN!



**The European Society of Hypertension
cares about the planet!**

In the occasion of the upcoming meeting in Athens, we will act to reduce the amount of printed paper, to use less water, conserve energy, help preserve adult trees and contribute reducing the global CO2 emissions.

For this reason, the Scientific Programme will be available only in digital version. No printed version will be provided.

You can find it on the event APP ESH Annual Meetings,
download it from www.esh2022.eu
or scanning this QR Code!






PLATFORM OVERVIEW



HOME PAGE

From the **HOME PAGE**, you will access to the different platform sections, virtually entering in the meeting rooms and actively participating thanks to the interaction tools available.



AGENDA

Scrolling down the home page, or selecting the label, you can access the complete programme divided by days and rooms.

Selecting the icon on the top right corner of each label, it is possible to add the specific session on your agenda.

NOTE: the timing you find in each session are expressed in EEST (Eastern European Summer Time).

Please make sure to convert them to your own time zone when preparing your agenda for the meeting.

TIME ZONE EET (UTC + 2h)

My agenda

Timetable

← 17 June

18 JUNE

19 June →

	Auditorium - A. Trianti	Mitropoulos	Skalkotas	Banqueting	MC 2
07:45	JOINT SESSION ESH-INDIAN Reducing cardiovascular risk in hypertension	BREAKFAST SESSION Modern lifestyle* and hypertension	BREAKFAST SESSION Pulse wave velocity in the clinic – measurement or	BREAKFAST SESSION How to interpret and manage heart rate in hypertension	BREAKFAST SESSION salt and potassium intake; hypertension and cardiovascular damage
08:00					
08:45		WORKSHOP Hypertension treatment targets in the elderly; new data and old problems	BREAKFAST SESSION Pulse wave velocity in the clinic – measurement or	ORAL SESSION 21 Diabetes and obesity	HOW-TO SESSION Managing hypertension and cvd risk in patients with ckd
09:00					
09:30					
10:00					
10:15					
11:00	PLENARY SESSION 5		WORKSHOP Renal denervation – from science to clinical practice	MEET-THE-EXPERT novelties in the diagnosis and management of primary aldosteronism	
12:30					
13:00		WORKSHOP Prevention in children and adolescents			
13:30					
14:00	TEACHING SEMINAR SESSION 3 Evaluating the Whole spectrum of difficult to control (resistant) hypertension				WORKSHOP inflammation, immunity and the arterial damage: what have we learned from the covid-19 pande
14:30					
14:15			JOINT SESSION Esh-heart failure association (hfa) from hypertension to heart failure		
14:30					

ON-DEMAND

In this section, you can access all online contents for three months after the congress (until September 20, 2022)

On-Demand

Search by title, subtitle or topic

Select tag



**BREAKFAST
SESSION**

Topic name
LOREM IPSUM DOLOR SIT AMET



**CLINICAL
CASE**

Topic name
LOREM IPSUM DOLOR SIT AMET



**HOW-TO
SESSION**

Topic name
LOREM IPSUM DOLOR SIT AMET



**JOINT
SESSION**

Topic name
LOREM IPSUM DOLOR SIT AMET



**MEET THE
EXPERT**

Topic name
LOREM IPSUM DOLOR SIT AMET



**ORAL
SESSION**

Topic name
LOREM IPSUM DOLOR SIT AMET



**PLENARY
SESSION**

Topic name
LOREM IPSUM DOLOR SIT AMET



**REGIONAL
SESSION**

Topic name
LOREM IPSUM DOLOR SIT AMET



**SPONSORED
SESSION**

Topic name
LOREM IPSUM DOLOR SIT AMET



**TEACHING
SEMINAR**

Topic name
LOREM IPSUM DOLOR SIT AMET



**WORKING
GROUP**

Topic name
LOREM IPSUM DOLOR SIT AMET



WORKSHOP

Topic name
LOREM IPSUM DOLOR SIT AMET

SOCIAL PROGRAMME

Opening Ceremony & Welcome Cocktail

Date: Friday, June 17

Venue: Megaron Conference Centre, Trianti Hall

Presidential Dinner

Date: Sunday, June 19

Venue: ACROPOLIS MUSEUM

Hellenic Society of Hypertension Meeting

The ESH Annual Meeting is being anticipated by the Hellenic Antihypertensive Congress, which is taking place at Megaron Athens International Conference Centre (MAICC) starting from June 16th afternoon until today, lunch time.

This solution allows greek delegates to attend both meetings with a unique registration fee.

Sponsorship packages *ad hoc* for Hellenic companies has been created, to give the opportunity to be part of the European Meeting and increase their visibility at international level.

Website & digital promotion

The official congress website www.esh2022.eu is active and constantly updated.

As done in the past, we are promoting the Annual Meeting on social media with a special focus on Twitter and Facebook, and through email blast to be sent to our mailing list, communicating all the congress updates and insights.

- Twitter: 1.300 followers



[@ESH_Annual](#) / [@ESHypertension](#) /

- Facebook: 668 followers



[@kreutzreinhold](#)
[@ESHAnnualMeetings](#)

#ESH2022

14.a ESH Awards 2022 (R. Kreutz)

ESH Awards Committee: Andrzej Januszewicz, Reinhold Kreutz, Empar Lurbe, Giuseppe Mancia, Konstantinos Tsioufis

The following ESH Awards will be presented in 2022:

Award	Recipient
Alberto Zanchetti Life Achievement Award	Jose Patricio López-Jaramillo
Björn Folkow Award and Lecture	Costas Thomopoulos
Honorary Membership	Bonita Falkner
Honorary Membership	Venkata Ram

A new selection committee has decided on this year's **Talal Zein Awards**: Jan Danser (lead), Jana Brguljan and Aleksander Prejbisz.

→ The Awards will be given to the 3 best oral presentations and 3 best poster presentations.

Also, the Paul A. Milliez Award will be presented to Philippe Gosse by the French Society and ESH.

The ESH Award Ceremony will take place on June 19 at 4:30 PM EEST in room A. Trianti at the Megaron.

14.b 2023 ESH Annual Meeting, Milan (G. Mancia, M. Massaro)

Dates: June 23 to 26, 2023

Venue: MiCo Milano Congressi – MILAN



Organising and Scientific Secretariat

AIM Group International (Rome, Italy)

14.c 2024 ESH Annual Meeting, Berlin (R. Kreutz, M. Massaro)




Presidents of the meeting: R. Kreutz, R. Schmieder

Dates: May 30 to June 3, 2024

Venue: Estrel Congress Center - BERLIN

Preliminary program structure



15. Interaction with National Societies (A. Januszewicz)

Meetings with Representatives of National Hypertension Societies in Athens

- From June 18 – 20, 2022 from 7:45 to 9:00 AM, Room MC 3.5 at Megaron

June 18, 2022	June 19, 2022	June 20, 2022
Finnish Society	Lithuanian Society	Israeli Society
Spanish Society	Polish Society	Swiss Society
French Society	German Society	Swedish Society
Austria Society	Portuguese Society	Norwegian Society
British & Irish Society	Czech Society	Hellenic Society

16. ESH Satellite Meetings & Endorsed Meetings (A. Januszewicz)

16.a Satellite Meetings 2022 (after Athens) & 2023

September 16-17, 2022 in Port Heli, Greece: organized by A. Manolis

15th ESH Post Congress Satellite Symposium – 30 Years of Cardiovascular Continuum: „From Hypertension and Risk Factors to Target Organ Damage“ (organized by the ESH WG on Hypertension and the Heart)

There is no official satellite planned so far for 2023.

16.b Endorsed Meetings 2022 (after Athens)

There is no officially endorsed meeting planned so far for the second half of 2022.

17. Any other issues (A. Januszewicz)

18. Dates for future Council Meetings (A. Januszewicz)

- 18.a Future Council Meetings (R. Kreutz) → see next slide
- 18.b Fall Council Meeting (A. Januszewicz)
- 18.c January / February 2023, Milan (A. Januszewicz)
in conjunction with the Program Committee Meeting
- 18.d Council Meeting on Friday, June 23, 2023, Milan (A. Januszewicz)
in conjunction with the ESH 2023 Annual Meeting

19. Closure of the meeting (R. Kreutz)